Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) and Integrated BioPharma (OTCMKTS:INBP – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider and Institutional Ownership
70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 67.4% of Integrated BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and target prices for Ernexa Therapeutics and Integrated BioPharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ernexa Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
Earnings & Valuation
This table compares Ernexa Therapeutics and Integrated BioPharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ernexa Therapeutics | $580,000.00 | 12.31 | -$14.08 million | ($26.20) | -0.23 |
| Integrated BioPharma | $54.35 million | 0.11 | $810,000.00 | ($0.07) | -2.70 |
Integrated BioPharma has higher revenue and earnings than Ernexa Therapeutics. Integrated BioPharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ernexa Therapeutics and Integrated BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ernexa Therapeutics | N/A | -263.74% | -151.16% |
| Integrated BioPharma | -3.43% | -8.32% | -6.57% |
Volatility & Risk
Ernexa Therapeutics has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500.
Summary
Ernexa Therapeutics beats Integrated BioPharma on 8 of the 14 factors compared between the two stocks.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
